A New Era of Prostate Cancer Precision Medicine

Adil Malik; Srilakshmi Srinivasan; Jyotsna Batra

doi:10.3389/fonc.2019.01263

A New Era of Prostate Cancer Precision Medicine

Front Oncol. 2019 Nov 26:9:1263. doi: 10.3389/fonc.2019.01263. eCollection 2019.

Authors

Adil Malik^{1

2}, Srilakshmi Srinivasan^{1

2}, Jyotsna Batra^{1

2}

Affiliations

¹ School of Biomedical Sciences, Queensland University of Technology, Institute of Health and Biomedical Innovation, Brisbane, QLD, Australia.
² Australian Prostate Cancer Research Centre-Queensland, Translational Research Institute, Woolloongabba, QLD, Australia.

Abstract

Prostate cancer is the second most common male cancer affecting Western society. Despite substantial advances in the exploration of prostate cancer biomarkers and treatment strategies, men are over diagnosed with inert prostate cancer, while there is also a substantial mortality from the invasive disease. Precision medicine is the management of treatment profiles across different cancers predicting therapies for individual cancer patients. With strategies including individual genomic profiling and targeting specific cancer pathways, precision medicine for prostate cancer has the potential to impose changes in clinical practices. Some of the recent advances in prostate cancer precision medicine comprise targeting gene fusions, genome editing tools, non-coding RNA biomarkers, and the promise of liquid tumor profiling. In this review, we will discuss these recent scientific advances to scale up these approaches and endeavors to overcome clinical barriers for prostate cancer precision medicine.

Keywords: biomarkers; gene fusion; genome editing; liquid biopsy; non-coding genome; precision medicine; prostate cancer; proteomic technologies.

Publication types

Review